Renal Cell Carcinoma (RCC)NCT07181954
CT-based Radiomics for Prediction of MIT Family Translocation Kidney Cancer: a Multicenter, Retrospective Clinical Study
An observational study of Renal Cell Carcinoma (RCC), run by First Affiliated Hospital of Fujian Medical University.
Trial summary
This project intends to construct a multicenter retrospective study, retrospectively collect clinical, imaging, pathological and prognostic data of patients, establish a complete data management system, establish a prediction model based on CT radiomics characteristics by combining radiomics, and verify the internal… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Renal Cell Carcinoma (RCC)
- How many people
- 746 participants
- Where
- No sites listed yet
- Study dates
- 15 Jan 2016to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Retrospective data collection was conducted from January 2009 to December 2023 at the First Affiliated Hospital of Fujian Medical University, the Provincial Hospital Affiliated to Fuzhou University, the Second Affiliated Hospital of Fujian Medical University, the First Affiliated Hospital of Chongqing Medical University, and the First Affiliated Hospital of Xiamen University.
Who may be able to join
- Pathological diagnosis of RCC;
- Have complete clinical, pathological and follow-up data;
- Renal CT plain scan and enhanced images can be obtained from the image storage and transmission system (PACS)
Who cannot join
- Patients who are not suitable for treatment: patients with severe comorbidities or unable to receive any form of treatment;
- Combined with other malignant tumors: have been treated with other malignant tumors (or have other untreated active malignancies at the same time);
- Patients with poor CT image quality/absence;
- Patients with missing clinical/pathological/follow-up data
About this study
This project intends to construct a multicenter retrospective study, retrospectively collect clinical, imaging, pathological and prognostic data of patients, establish a complete data management system, establish a prediction model based on CT radiomics characteristics by combining radiomics, and verify the internal and external sequence of the model, which will improve the preoperative clinical diagnosis level of MIT family translocation kidney cancer, and then guide personalized and precise diagnosis and treatment.
- Conditions
- Renal Cell Carcinoma (RCC)
- Keywords
- Renal Cell Carcinoma, Computed Tomography, MIT
- Medical subject headings
- Carcinoma, Renal Cell
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative renal tumor pathological diagnosis type
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2025
- Study start15 Jan 2016
- Primary completion15 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal Cell Carcinoma (RCC)Studies of the same condition, open and under way.
- More trials run by First Affiliated Hospital of Fujian Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 746 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07181954
- Sponsor's protocol ID
- MRCTA, ECFAH of FMU [2025]794
- Status last verified
- Sep 2025
- First submitted
- 12 Sep 2025
- Last updated
- 19 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CT-based Radiomics for Prediction of MIT Family Translocation Kidney Cancer: a Multicenter, Retrospective Clinical Study
- ClinicalTrials.gov ID
- NCT07181954
- Acronym / sponsor ID
- MRCTA, ECFAH of FMU [2025]794
- Conditions
- Renal Cell Carcinoma (RCC)
- Keywords
- Renal Cell Carcinoma, Computed Tomography, MIT
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 746 participants (actual)
- Lead sponsor
- First Affiliated Hospital of Fujian Medical UniversityUniversity, hospital or other
- Study start
- 15 Jan 2016 (actual)
- Primary completion
- 15 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 19 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project intends to construct a multicenter retrospective study, retrospectively collect clinical, imaging, pathological and prognostic data of patients, establish a complete data management system, establish a prediction model based on CT radiomics characteristics by combining radiomics, and verify the internal and external sequence of the model, which will improve the preoperative clinical diagnosis level of MIT family translocation kidney cancer, and then guide personalized and precise diagnosis and treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Retrospective data collection was conducted from January 2009 to December 2023 at the First Affiliated Hospital of Fujian Medical University, the Provincial Hospital Affiliated to Fuzhou University, the Second Affiliated Hospital of Fujian Medical University, the First Affiliated Hospital of Chongqing Medical University, and the First Affiliated Hospital of Xiamen University.
Key inclusion criteria (3 listed)
- Pathological diagnosis of RCC;
- Have complete clinical, pathological and follow-up data;
- Renal CT plain scan and enhanced images can be obtained from the image storage and transmission system (PACS)
Key exclusion criteria (4 listed)
- Patients who are not suitable for treatment: patients with severe comorbidities or unable to receive any form of treatment;
- Combined with other malignant tumors: have been treated with other malignant tumors (or have other untreated active malignancies at the same time);
- Patients with poor CT image quality/absence;
- Patients with missing clinical/pathological/follow-up data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Postoperative renal tumor pathological diagnosis type
Time frame: 1 week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Renal Cell Carcinoma (RCC)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 2
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Localized Clear Cell Renal Cell Carcinoma
Active, not recruitingPhase 1/2
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Cell Carcinoma (RCC), run by First Affiliated Hospital of Fujian Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative renal tumor pathological diagnosis type (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2025.